Personal Capital Advisors’s Marker Therapeutics MRKR Stock Holding History

Personal Capital Advisors’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$6.84K	Hold	2,571	–	–	﹤0.01%	488
2022 Q3	$9K	Hold	2,571	–	–	﹤0.01%	453
2022 Q2	$8K	Hold	2,571	–	–	﹤0.01%	441
2022 Q1	$11K	Hold	2,571	–	–	﹤0.01%	490
2021 Q4	$24K	Hold	2,571	–	–	﹤0.01%	543
2021 Q3	$43K	Hold	2,571	–	–	﹤0.01%	492
2021 Q2	$72K	Hold	2,571	–	–	﹤0.01%	480
2021 Q1	$58K	Hold	2,571	–	–	﹤0.01%	469
2020 Q4	$37K	Hold	2,571	–	–	﹤0.01%	451
2020 Q3	$39K	Hold	2,571	–	–	﹤0.01%	411
2020 Q2	$53K	Hold	2,571	–	–	﹤0.01%	358
2020 Q1	$49K	Hold	2,571	–	–	﹤0.01%	340
2019 Q4	$74K	Hold	2,571	–	–	﹤0.01%	394
2019 Q3	$131K	Buy	+2,571	New	+$152K	﹤0.01%	358
2019 Q2	–	Sell	-2,571	Closed	-$170K	–	340
2019 Q1	$170K	Hold	2,571	–	–	﹤0.01%	320
2018 Q4	$143K	Buy	+2,571	New	+$187K	﹤0.01%	302

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MAA

Matrix Asset Advisors White Plains, New York $1.23B AUM 26.4% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Personal Capital Advisors's MRKR Position: Q4 2022 in Review

Personal Capital Advisors held its Marker Therapeutics (MRKR) position steady in Q4 2022 at 2,571 shares worth $6.84K. The position accounts for ﹤0.01% of the portfolio, ranked #488.

Personal Capital Advisors first reported a position in MRKR in Q4 2018 and has held it in 16 quarters since. The position peaked at $170K in Q1 2019. 47 funds tracked by Wall St. Rank hold MRKR as of Q4 2022.

Personal Capital Advisors held 2,571 shares of Marker Therapeutics worth $6.84K as of Q4 2022.
Personal Capital Advisors left its Marker Therapeutics share count unchanged in Q4 2022.
Marker Therapeutics made up ﹤0.01% of Personal Capital Advisors's portfolio in Q4 2022, its #488 holding.
Personal Capital Advisors first reported a position in Marker Therapeutics in Q4 2018 and has held it in 16 quarters since.
Personal Capital Advisors's Marker Therapeutics position peaked at $170K in Q1 2019.
47 funds tracked by Wall St. Rank held Marker Therapeutics as of Q4 2022.

Based on Personal Capital Advisors's 13F filing for Q4 2022, filed 15 Feb 2023.